Moyamoya Disease Drug Market Share

  • Report ID: 3383
  • Published Date: Nov 29, 2023
  • Report Format: PDF, PPT

Moyamoya Disease Drug Market Share

North American Market Forecast

The moyamoya disease market in the North America region is predicted to hold the largest share of about 33% during the forecast period. Major pharmaceutical businesses operating in the area and significant investments being made in the development of novel and cutting-edge pharmaceuticals are the main drivers of the market's growth in this region. Moreover, there has been an increase in the number of people facing problems due to obesity in the region. The United States also has one of the largest percentages of obese people worldwide. Data gathered between 2017 and 2020 indicates that 41.9% of adult Americans are obese. From 2017 to March 2020, the US had a 41.9% obesity prevalence rate.

APAC Market Statistics

The moyamoya disease market in the Asia Pacific region is projected to hold the second-largest share of about 27% during the projected period. The growth of the market in this region is owing to the increasing prevalence of moyamoya disease in the region, backed by the busy and hectic lifestyle of people. Furthermore, improving healthcare facilities is also estimated to boost market growth.

Research Nester
Get more information on this report: Request Free Sample PDF

Browse Key Market Insights with Data Illustration:


Author Credits:  Radhika Pawar


  • Report ID: 3383
  • Published Date: Nov 29, 2023
  • Report Format: PDF, PPT

Frequently Asked Questions (FAQ)

Increasing cases of moyamoya disease, and more people opting for medications over surgery to act as major market growth driver.

The market size of moyamoya disease is anticipated to attain a CAGR of 5.5% over the forecast period, i.e., 2024-2036.

The major players in the market are Merck & Co., Inc., Siemens Healthcare GmbH, Boston Scientific Corporation, Johnson & Johnson Services, Inc., Valenta Pharmaceuticals Company, Novartis AG, Sanofi-Aventis Groupe, AbbVie Inc., Elli Lilly and Company, and others.

The calcium channel blocker segment is anticipated to garner the largest market size by the end of 2036 and display significant growth opportunities.

The market in the North America region is projected to hold the largest market share by the end of 2036 and provide more business opportunities in the future.
Inquiry Before Buying Request Free Sample
logo
  GET A FREE SAMPLE

FREE Sample Copy includes market overview, growth trends, statistical charts & tables, forecast estimates, and much more.

 Request Free Sample Copy

Have questions before ordering this report?

Inquiry Before Buying
Inquiry Before Buying Request Free Sample